GlassScriptPhysician profile
Thomas Owen Crawford
NPI 1104866110
$214,607.82
in general payments reported to CMS, 2019-2025
9 companies · $437 in 2025
The $437 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $22K · 2021: $15K · 2022: $23K · 2023: $1,074 · 2024: $103K · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $103K · Food and Beverage: $1,722 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $103,143.50 |
| Food and Beverage | $1,722.19 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $117.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $96,707.50 | 2024 | |
| Biogen, INC. | $75,115.74 | 2019-2025 | Spinraza |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $28,169.97 | 2019-2023 | Zolgensma |
| Genentech USA, INC. | $7,613.06 | 2020-2024 | Evrysdi |
| Sarepta Therapeutics, INC. | $6,726.64 | 2020-2024 | Elevidys |
| Itf Therapeutics LLC | $177.55 | 2024-2025 | |
| Genentech, INC. | $73.29 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.07 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Crawford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.